Gilead Acquires Ouro Medicines for Up to $2.18 Billion to Advance T Cell Engager Autoimmune Therapies

on

Gilead Sciences announced a definitive agreement to acquire Ouro Medicines for $1.675 billion in upfront cash consideration plus up to $500 million in contingent milestone payments, totaling up to $2.18 billion12

The acquisition adds OM336 (gamgertamig), a clinical-stage BCMAxCD3 T cell engager designed for rapid and deep B cell depletion in autoimmune diseases1

OM336 has demonstrated transformative efficacy in Phase 1/2 studies for severe antibody-mediated orphan diseases including autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) after a single treatment cycle1

OM336 has received Orphan Drug Designation and Fast Track Designation from the FDA and is expected to enter registrational studies in 202712

Gilead is in advanced discussions with Galapagos for a strategic research and development collaboration where Galapagos would pay 50% of upfront costs and contingent milestones, absorb Ouro's operating assets and employees, and handle development costs through registrational studies1

Gilead will retain worldwide commercialization rights (except in Greater China where Keymed Biosciences holds existing rights) and will pay Galapagos royalties of 20%-23% of net sales1

Ouro Medicines was founded in 2025 by Monograph Capital in partnership with GSK and is backed by investors including TPG, NEA, and Norwest1

Sources:

1. https://www.businesswire.com/news/home/20260323998270/en/Gilead-Sciences-to-Acquire-Ouro-Medicines-to-Advance-First-in-Class-T-Cell-Engager-Program-for-Autoimmune-Diseases

2. https://www.morningstar.com/news/dow-jones/202603238393/gilead-sciences-to-buy-ouro-medicines-for-up-to-218-billion